

Inderprit Singh  
Compliance Adviser, Listings Compliance (Sydney)  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

26 March 2024

## Notice Under Section 708AA(2)(f) Corporations Act

This notice (**Notice**) is given by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (ASX: CU6) (**Company** or **Clarity**).

Clarity has today announced a fully underwritten pro-rata accelerated non-renounceable entitlement offer (**Offer**) of approximately 7,973,485 shares on the basis of 1 new fully paid ordinary share (each a **New Share**, and collectively, the **New Shares**) for every 33 ordinary shares in Clarity held by eligible existing shareholders in Clarity as at 7.00pm (AEDT) on Thursday, 28 March 2024 at a price of A\$2.55 per New Share.

The Company advises that:

- a) the New Shares will be offered without disclosure to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Corporations Act**);
- b) this Notice is issued pursuant to section 708AA(2)(f) of the Corporations Act as modified by ASIC;
- c) as at the date of this Notice, the Company has complied with:
  - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - ii. sections 674 and 674A of the Corporations Act;
- d) as at the date of this Notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act that is required to be set out in this notice; and
- e) the potential effect the issue of the New Shares under the Offer will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. Given the structure of the Offer as a pro-rata issue and the current level of holdings of substantial holders, the Offer is not expected to have any material effect or consequence on the control of the Company.

Robert Vickery  
Company Secretary

*This announcement has been authorised for release by the Executive Chairperson.*

**For more information, please contact:**

Clarity Pharmaceuticals  
Dr Alan Taylor  
Executive Chairperson  
[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

**About Clarity Pharmaceuticals**

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

***[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)***